Build status - In Progress

MG0003 A Phase 3 Randomized Double-Blind Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis

MG0003 A Phase 3 Randomized Double-Blind Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis
Recruiting
18 years - 99 years
All
Phase 3
4 participants needed
1 Location

Brief description of study

This is a Phase 3 study of rozanolixizumab in anti-AChR or anti-MuSK autoantibody-positive patients with generalized MG who experience moderate to severe symptoms and are being considered for treatment with IVIg or PEX. The primary objective of the study is to demonstrate the clinical efficacy of rozanolixizumab in patients with generalized Myasthenia Gravis.

All participants will be consented and enrolled by the Penn PI or Sub-I. Referrals will be accepted but we plan to recruit patients from within Penn Medicine clinics. 


Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: myasthenia gravis
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 833604

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center